AREA UNDER THE CURVE;
CLINICAL TRIAL;
DRUG CLEARANCE;
DRUG HALF LIFE;
DRUG RESPONSE;
DRUG SAFETY;
HUMAN;
INFECTION;
JOINT DESTRUCTION;
MAXIMUM PLASMA CONCENTRATION;
RESPIRATORY TRACT DISEASE;
RHEUMATOID ARTHRITIS;
SHORT SURVEY;
T LYMPHOCYTE ACTIVATION;
METABOLISM;
REVIEW;
Abatacept improves American College of Rheumatology responses and Disease Activity Score 28 remission rates in both recent-onset and more established rheumatoid arthritis: Results from the AIM trial [presentation 1494]
November 13-17, San Diego, Calif
J Kremer et al. Abatacept improves American College of Rheumatology responses and Disease Activity Score 28 remission rates in both recent-onset and more established rheumatoid arthritis: results from the AIM trial [presentation 1494]. Annual meeting of the American College of Rheumatology; November 13-17, 2005; San Diego, Calif.
Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients receiving background disease modifying anti-rheumatic drugs (DMARDs): The ASSURE trial [presentation 1918]
November 13-17, San Diego, Calif
B Combe et al. Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients receiving background disease modifying anti-rheumatic drugs (DMARDs): the ASSURE trial [presentation 1918]. Annual meeting of the American College of Rheumatology; November 13-17, 2005; San Diego, Calif.
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
LW Moreland et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470.
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
JM Kremer et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263.
Safety of abatacept in rheumatoid arthritis patients in five double-blind placebo-controlled trials [presentation 886]
November 13-17, San Diego, Calif
L Moreland et al. Safety of abatacept in rheumatoid arthritis patients in five double-blind placebo-controlled trials [presentation 886]. Annual meeting of the American College of Rheumatology; November 13-17, 2005; San Diego, Calif. 19-20
